Radical polymerizable macrocyclic resin compositions with low polymerization stress

Information

  • Patent Grant
  • 8129446
  • Patent Number
    8,129,446
  • Date Filed
    Wednesday, October 27, 2010
    13 years ago
  • Date Issued
    Tuesday, March 6, 2012
    12 years ago
Abstract
A composition of macrocyclic oligomer with at least one (meth)acrylate polymerizable group. A method includes preparing an activated precursor of an oligomer at pseudo high-dilution conditions. A method also includes preparing an activated precursor of an oligomer by reacting the precursor with an activated coupling agent, wherein the precursor is condensable and polymerizable.
Description
FIELD OF THE INVENTION

This invention relates to free radical polymerizable macrocyclic compounds and composition, which feature by their low shrinkage and low contraction stress upon polymerization. Such low shrinkage and low stress resin could find their wide range of applications, especially in microelectronic, special coating and restorative dentistry where the dimensional stability and contraction stress within cured materials are critical to the total performance.


BACKGROUND OF THE INVENTION

The polymerization shrinkage of curable material is referred to the dimensional contraction during polymerization or curing, because the formation of covalent bonding during polymerization bring the molecules closer each other than that while they are free in van der Walls distance. The origin of polymerization stress, on the other hand, comes from a restrained polymerization or shrinking during curing. Therefore, it is not only related to polymerization shrinkage, but also is dependent on the polymerization kinetics.


It is well known that with increasing molecular weight, the mobility of polymeric chain would be limited, the diffusion is becoming the rate control factor. In addition, such a limited mobility in a cross-linking system appear to come earlier in comparison with linear system, which means extra reaction would lead to an increasing polymerization stress. There are different ways to control the stress generation and development:


1. Slow down the polymerization rate;

    • Introducing a special rate controller like stable radicals;
    • Creating different polymerization zones from which the stress developed in a polymerized zone could be transferred to its adjacent unpolymerized zone and got relief like segmental polymerization technique;
    • Employing different polymerization groups;
    • Using large-size macromonomer to limited its reactivity at the early stage;


2. Reduce the conversion;

    • Pre-building a 2D or 3D structure like macrocyclics, dendrimers or hyperbranches;


3. Limiting the cross-link density to offer acceptable mechanical property.


To reduce polymerization shrinkage and stress in the specific dental restorative composite, all of above approaches are taking into account. In this invention, however, the objective is to present a general method to produce a macrocyclic oligomer which would be converted into 3D network via free radical polymerization.


U.S. Pat. No. 4,644,053, disclosed a method to synthesize single macrocyclic compounds. Then various macrocyclics oligomers, including carbonates, esters, amides, ethers, imides, sulfides, et al, have been prepared. However, high temperature ring-opening reaction has to be involved to convert these macrocyclics into high molecular weight polymers.


U.S. Pat. No. 5,047,261, disclosed a composition containing a five-member carbonate cyclic group for fast copolymerization with methacrylate.


U.S. Pat. No. 5,792,821, disclosed polymerizable cyclidextrin (CD) derivatives, in which methacrylate was attached on CD.


U.S. Pat. No. 5,962,703, disclosed functionalized bicyclic methacrylate with norboneyl or norbonadienl group.


U.S. Pat. No. 6,043,361, disclosed polymerizable cyclic allylic sulfides is used for low shrinkage materials.







APPROACH

The macrocyclic oligomers are prepared under pseudo-high-dilution condition via a condensation between a reactive and free radical polymerizable precursor and various coupling agents to afford carbonate, ester, siloxane, phosphonate, et al linkages to result in macrocyclic oligomers. To avoid the premature polymerization of methacrylate groups, the condensation groups usually have to be activated to assure a mild reaction for cyclization with the coupling monomers.


BisGMA is one of widely used dental resin and it contains two free radical polymerizable group, methacrylate and two hydroxyl groups. This turns BisGMA an ideal candidate for polymerizable macrocyclic oligomer, although the presence of BisGMA isomer would make more complicated to this approach. As shown in Scheme I, carbonyldiimidazol (CDI, 1), was used to selectively reacted with the secondary alcohol in BisGMA (2) to give an activated BisGMA, DIZ-BisGMA(3). It was isolated and the chemical structure of DIZ-BisGMA was fully characterized with FITR and NMR. Actually, according to the recent report by Davis et al of Courtlaulds, England, CDI and its intermediates could exhibit surprisingly specificity towards primary, secondary, tertiary functional groups, of the same type, during the controlled formation of various well-defined molecular sequence. Our idea is to adopt same chemistry of CDI and to activate the two secondary hydroxyl group. Furthermore, an activated precursor, DIZ-BisGMA, was made to react with various primary diols 1,10-decanediol, under a pseudo high-dilution condition, as shown in Scheme II. Both reactants were simultaneously charged into the system in a high-dilution condition via slowly, precisely controlled addition to ensure a favorable formation of cyclic product. Since the product, C10-CYCBGM (5), is accumulated with a final concentration of 0.02M, which is much higher than the classical high dilution condition (0.001M), this procedure is, therefore, referred as pseudo-high-dilution approach. Since imidazol is produced from both precursor and cyclization steps, a continuous process was successfully developed without direct separation of DIZ-BisGMA.




embedded image




embedded image




embedded image

Claims
  • 1. A method of forming a macrocyclic oligomer, comprising: condensing a reactive and free radical polymerizable precursor and a coupling agent resulting in formation of the macrocyclic oligomer,wherein the macrocyclic oligomer is present in solution with a final concentration of 0.02M, andwherein the polymerizable precursor is DIZ-BisGMA and the coupling agent is a primary diol.
  • 2. The method of claim 1, wherein the primary diol is 1,10-decanediol.
  • 3. The method of claim 1, wherein the macrocyclic oligomer is
  • 4. A macrocyclic oligomer having the structure of
RELATED APPLICATIONS

This is a Continuation Application which claims priority to U.S. Ser. No. 12/655,028 filed on Dec. 22, 2009, now abandoned, which claims priority to U.S. Ser. No. 12/381,781 filed on Mar. 16, 2009, now abandoned, which claims priority to U.S. Ser. No. 12/079,525 filed on Mar. 27, 2008, now abandoned, which in turn claims priority to U.S. Ser. No. 11/153,090 filed on Jun. 15, 2005, now abandoned, which in turn claims priority to provisional patent application Ser. No. 60/579,836 filed on Jun. 15, 2004, now abandoned.

US Referenced Citations (59)
Number Name Date Kind
4131729 Schmitt et al. Dec 1978 A
4323348 Schmitz-Josten et al. Apr 1982 A
4323696 Schmitz-Josten et al. Apr 1982 A
4379695 Orlowski et al. Apr 1983 A
4407984 Ratcliffe et al. Oct 1983 A
4459193 Ratcliffe et al. Jul 1984 A
4644053 Brunelle et al. Feb 1987 A
4722947 Thanawalla et al. Feb 1988 A
4744827 Winkel et al. May 1988 A
5047261 Moussa et al. Sep 1991 A
5110893 Fukuyama May 1992 A
5321117 Brunelle Jun 1994 A
5444104 Waknine Aug 1995 A
5609675 Noritake et al. Mar 1997 A
5621119 Podszun et al. Apr 1997 A
5760142 Klee Jun 1998 A
5792821 Bowen Aug 1998 A
5846075 Shu et al. Dec 1998 A
5856374 Ono et al. Jan 1999 A
5886064 Rheinberger et al. Mar 1999 A
5944527 Hasel Aug 1999 A
5962703 Moszner et al. Oct 1999 A
5998499 Klee et al. Dec 1999 A
6022940 Byerley et al. Feb 2000 A
6031015 Ritter et al. Feb 2000 A
6037444 Rannard et al. Mar 2000 A
6043361 Evans et al. Mar 2000 A
6057460 Moszner et al. May 2000 A
6096903 Moszner et al. Aug 2000 A
6121344 Angeletakis et al. Sep 2000 A
6127450 Angeletakis Oct 2000 A
6147136 Bissinger Nov 2000 A
6177534 Antonucci et al. Jan 2001 B1
6184339 Stansbury et al. Feb 2001 B1
6187836 Oxman et al. Feb 2001 B1
6204302 Rawls et al. Mar 2001 B1
6232367 Kobashigawa et al. May 2001 B1
6262142 Wang et al. Jul 2001 B1
6344556 Evans et al. Feb 2002 B1
6353040 Subelka et al. Mar 2002 B1
6353061 Klee et al. Mar 2002 B1
6376026 Correll et al. Apr 2002 B1
6380347 Lau et al. Apr 2002 B1
6384106 Angeletakis May 2002 B1
6391940 Blackwell et al. May 2002 B1
6395803 Angeletakis May 2002 B1
6399037 Pflug et al. Jun 2002 B1
6448301 Gaddam et al. Sep 2002 B1
6495643 Evans et al. Dec 2002 B1
6566413 Weinmann et al. May 2003 B1
20020025993 Klee et al. Feb 2002 A1
20020068771 Klee et al. Jun 2002 A1
20020128347 Blackwell et al. Sep 2002 A1
20030060535 Moszner et al. Mar 2003 A1
20030125435 Norling et al. Jul 2003 A1
20040077882 Moszner et al. Apr 2004 A1
20040106741 Kriessel et al. Jun 2004 A1
20050154199 Whiteford et al. Jul 2005 A1
20060063854 Jin et al. Mar 2006 A1
Foreign Referenced Citations (5)
Number Date Country
9702787 Jan 1997 WO
9917677 Apr 1999 WO
0003688 Jan 2000 WO
0195862 Dec 2001 WO
2005123008 Dec 2005 WO
Related Publications (1)
Number Date Country
20110152569 A1 Jun 2011 US
Continuations (1)
Number Date Country
Parent 12655028 Dec 2009 US
Child 12912951 US